Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2003
05/08/2003WO2002048152A3 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
05/08/2003WO2002039953A9 Texaphyrin coordination compounds and uses thereof
05/08/2003WO2002026946A3 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof
05/08/2003WO2002026223A3 Catecholamine pharmaceutical compositions and methods
05/08/2003WO2002024715A3 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
05/08/2003WO2002020768A9 Caveolin peptides and their use as therapeutics
05/08/2003WO2002010216A3 Proteins and nucleic acids encoding same
05/08/2003US20030088312 Use of cladribine on a stent to prevent restenosis
05/08/2003US20030088111 Protected forms of pharmacologically active agents and uses therefor
05/08/2003US20030088085 MPROT12 polynucleotides and methods thereof
05/08/2003US20030088061 Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing an allosteric regulatory site
05/08/2003US20030087963 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
05/08/2003US20030087948 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
05/08/2003US20030087945 Sulfonylaminocarboxylic acids
05/08/2003US20030087939 Novel succinate derivative compounds useful as cysteine protease inhibitors
05/08/2003US20030087926 Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives
05/08/2003US20030087924 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
05/08/2003US20030087923 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
05/08/2003US20030087922 Aryl substituted 2-aminopyrimidines and 2-aminopyridines
05/08/2003US20030087921 Especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa.
05/08/2003US20030087919 Rho-kinase inhibitors
05/08/2003US20030087911 Methods and compositions for treating hypertension
05/08/2003US20030087910 E.g., O-(2-quinolinylmethyl)-N-quinaldoyl-D,L-tyrosine
05/08/2003US20030087907 Quinoline derivatives and quinazoline derivatives having azolyl group
05/08/2003US20030087903 Mevinolin derivatives
05/08/2003US20030087902 Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents
05/08/2003US20030087901 Compounds and methods for modulation of estrogen receptors
05/08/2003US20030087897 Containing carboxylic acid groups; diagnosis; prophylaxis
05/08/2003US20030087888 Anticancer agents
05/08/2003US20030087878 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003US20030087832 Anticancer agents; antidiabetic agents, anticholesterol agents, cardiovascular disorders, osteoporosis
05/08/2003US20030087831 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
05/08/2003US20030087821 Using exendrin, or antagonist thereof; appetite control
05/08/2003US20030087820 Novel exendin agonist formulations and methods of administration thereof
05/08/2003US20030087817 Regulation of endogenous gene expression in cells using zinc finger proteins
05/08/2003US20030087801 Methods for treatment using novel ligands of the neuropeptide receptor hfgan72
05/08/2003US20030087412 Nucleotide sequences coding polypeptide for use in the prevention and treatment of tumors, nervous system, cardiomyopathy, viral and metabolic diseases
05/08/2003US20030087341 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of autoimmune disease
05/08/2003US20030087306 Methods for identifying novel multimeric agents that modulate receptors
05/08/2003US20030087266 IGs as modifiers of the p53 pathway and methods of use
05/08/2003US20030087255 Peptides which stimulate the immune response and tissue regeneration
05/08/2003US20030086977 Forming a free- standing powder comprising at least one antimicrobial metal with atomic disorder; and injecting the free-standing powder in therapeutically effective amounts to the tissue which is to be treated
05/08/2003US20030086948 For decreasing the effect of intestinal metabolism on a drug
05/08/2003US20030086919 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
05/08/2003US20030086914 Method and device for inducing biological processes by micro-organs
05/08/2003US20030086898 Method for treating hypercholesterolemia with polyallylamine polymers
05/08/2003CA2756610A1 Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
05/08/2003CA2466824A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003CA2466424A1 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
05/08/2003CA2466152A1 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
05/08/2003CA2466032A1 Methods and dosage forms for improving the bioavailability of therapeutic agents
05/08/2003CA2465792A1 Non-neurotoxic plasminogen activating factors for treating of stroke
05/08/2003CA2465632A1 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
05/08/2003CA2465497A1 Bridged bicyclic amino acid-derived (1,4) benzodiazepine vasopressin receptor antagonists
05/08/2003CA2465438A1 Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells
05/08/2003CA2465350A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties
05/08/2003CA2465344A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties
05/08/2003CA2465316A1 Hydroxy substituted amides for the treatment of alzheimer's disease
05/08/2003CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
05/08/2003CA2465306A1 Substituted 1h-quinolin-2-one compounds
05/08/2003CA2465061A1 Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
05/08/2003CA2465040A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003CA2464997A1 Silicon compounds
05/08/2003CA2464995A1 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
05/08/2003CA2464956A1 Detection of haematopoietic stem cells and progeny and uses thereof
05/08/2003CA2464945A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
05/08/2003CA2464944A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003CA2464934A1 Pyrimido [4,5-b] indole derivatives
05/08/2003CA2464727A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
05/08/2003CA2464479A1 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003CA2464353A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003CA2464342A1 Therapeutic isoquinoline compounds
05/08/2003CA2464031A1 Purine analogs having hsp90-inhibiting activity
05/08/2003CA2463770A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003CA2463580A1 Polymer conjugates of protein kinase c inhibitors
05/08/2003CA2463441A1 Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
05/08/2003CA2463091A1 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
05/08/2003CA2462525A1 Type 4 phosphodiesterase inhibitors and uses thereof
05/08/2003CA2462206A1 Substituted thioacetamides
05/08/2003CA2460134A1 Peroxisome proliferator activated receptor ligand and process for producing the same
05/08/2003CA2426785A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/07/2003EP1308509A1 Novel physiologically active peptide and use thereof
05/07/2003EP1308446A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/07/2003EP1308445A1 5-heteroatom-substituted pyrazoles
05/07/2003EP1308441A1 2-aminopyridine compounds and use thereof as drugs
05/07/2003EP1308440A1 Piperidine derivatives and drugs containing these derivatives as the active ingredient
05/07/2003EP1308438A1 3-substituted urea derivatives and medicinal use thereof
05/07/2003EP1308179A1 Improved endoprosthetic device
05/07/2003EP1308166A1 Desmodus Salivary Plasminogen Activator (DSPA) for the treatment of strokes
05/07/2003EP1308161A1 5-N-heterocyclyl-1-(4-sulfonyl-phenyl)-1H-pyrazole derivatives with cyclooxygenase 2 (COX-2) inhibiting activity for the treatment of inflammatory diseases
05/07/2003EP1308158A1 Sulfonylaryl- and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/07/2003EP1307588A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF
05/07/2003EP1307582A2 Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
05/07/2003EP1307568A2 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
05/07/2003EP1307566A2 Mitogen activated kinase
05/07/2003EP1307557A2 Endothelial cell expression patterns
05/07/2003EP1307554A2 C3b/c4b complement receptor-like molecules and uses thereof
05/07/2003EP1307552A2 C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
05/07/2003EP1307550A1 Human 7tm protein receptors and polynucleotides encoding the same
05/07/2003EP1307486A2 Somatostatin analogues
1 ... 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 ... 1595